{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:40:30Z","timestamp":1791859230648,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Calcimimetics, shown to control biochemical parameters of secondary hyperparathyroidism (SHPT), have well-established safety and pharmacokinetic profiles in adult end-stage renal disease subjects treated with dialysis; however, such studies are limited in pediatric subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics\u00a0(PD) of cinacalcet were evaluated in children with chronic kidney disease (CKD) and SHPT receiving dialysis. Twelve subjects received a single dose of cinacalcet (0.25\u00a0mg\/kg) orally or by nasogastric or gastric tube. Subjects were randomized to one of two parathyroid hormone (PTH) and serum calcium sampling sequences: [(1) 2, 8, 48\u00a0h; or (2) 2, 12, 48\u00a0h] and assessed for 72\u00a0h after dosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median plasma cinacalcet<jats:italic>t<\/jats:italic><jats:sub>max<\/jats:sub>was 1\u00a0h (range 0.5\u20134.0\u00a0h); mean (SD)<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>and AUC<jats:sub>last<\/jats:sub>were 2.83 (1.98)\u00a0ng\/mL and 11.8 (8.74)\u00a0h*ng\/mL, respectively; mean (SD) half-life (<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>) was 3.70 (2.57)\u00a0h. Dose adjustments, based upon body weight (mg\/kg), minimized the effects of age, body weight, body surface area, and body mass index on cinacalcet PK. Reductions in serum PTH levels from baseline were observed at 2 to 8\u00a0h post-dose (median 10.8 and 29.6%, respectively), returned towards baseline by 12\u201372\u00a0h and were inversely related to changes in the plasma cinacalcet PK profile. Single-dose cinacalcet was well-tolerated with no unexpected safety findings and a PK\/PD, safety profile similar to adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In conclusion, a single 0.25\u00a0mg\/kg dose of cinacalcet was evaluated to be a safe starting dose in these children aged &lt;\u20096\u00a0years.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00467-018-4054-8","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T21:28:51Z","timestamp":1535059731000},"page":"145-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28\u00a0days to &lt;\u20096\u00a0years with chronic kidney disease receiving dialysis"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-1345","authenticated-orcid":false,"given":"Winnie Y.","family":"Sohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Portale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy L.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Ertik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Shahinfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Dehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Warady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"4054_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters. Kidney Int 92:26\u201336","journal-title":"Kidney Int"},{"key":"4054_CR2","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.2215\/CJN.02110216","volume":"11","author":"AA Portale","year":"2016","unstructured":"Portale AA, Wolf MS, Messinger S, Perwad F, Juppner H, Warady BA, Furth SL, Salusky IB (2016) Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol 11:1989\u20131998","journal-title":"Clin J Am Soc Nephrol"},{"key":"4054_CR3","first-page":"175","volume":"14","author":"J Silver","year":"1994","unstructured":"Silver J, Naveh-Many T (1994) Regulation of parathyroid hormone synthesis and secretion. Semin Nephrol 14:175\u2013194","journal-title":"Semin Nephrol"},{"key":"4054_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/ki.1997.297","volume":"52","author":"AM Parfitt","year":"1997","unstructured":"Parfitt AM (1997) The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52:3\u20139","journal-title":"Kidney Int"},{"key":"4054_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.pop.2008.01.007","volume":"35","author":"SM Moe","year":"2008","unstructured":"Moe SM (2008) Disorders involving calcium, phosphorus, and magnesium. Prim Care 35:215\u2013237 v-vi","journal-title":"Prim Care"},{"key":"4054_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.ki.5002287","volume":"74","author":"WG Goodman","year":"2008","unstructured":"Goodman WG, Quarles LD (2008) Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 74:276\u2013288","journal-title":"Kidney Int"},{"key":"4054_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913\u2013921","journal-title":"Clin J Am Soc Nephrol"},{"key":"4054_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2215\/CJN.05940611","volume":"7","author":"K Wesseling-Perry","year":"2012","unstructured":"Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, Juppner H, Salusky IB (2012) Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 7:146\u2013152","journal-title":"Clin J Am Soc Nephrol"},{"key":"4054_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1046\/j.1523-1755.2003.00727.x","volume":"63","author":"JW Groothoff","year":"2003","unstructured":"Groothoff JW, Offringa M, Van Eck-Smit BL, Gruppen MP, Van De Kar NJ, Wolff ED, Lilien MR, Davin JC, Heymans HS, Dekker FW (2003) Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int 63:266\u2013275","journal-title":"Kidney Int"},{"key":"4054_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.semnephrol.2012.12.017","volume":"33","author":"K Wesseling-Perry","year":"2013","unstructured":"Wesseling-Perry K, Salusky IB (2013) Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol 33:169\u2013179","journal-title":"Semin Nephrol"},{"key":"4054_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1681\/ASN.2015020152","volume":"27","author":"MR Denburg","year":"2016","unstructured":"Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB (2016) Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study. J Am Soc Nephrol 27:543\u2013550","journal-title":"J Am Soc Nephrol"},{"key":"4054_CR12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2165\/00148581-200305110-00005","volume":"5","author":"CP Sanchez","year":"2003","unstructured":"Sanchez CP (2003) Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Paediatr Drugs 5:763\u2013776","journal-title":"Paediatr Drugs"},{"key":"4054_CR13","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1359\/jbmr.1999.14.10.1680","volume":"14","author":"BD Kuizon","year":"1999","unstructured":"Kuizon BD, Salusky IB (1999) Growth retardation in children with chronic renal failure. J Bone Miner Res 14:1680\u20131690","journal-title":"J Bone Miner Res"},{"key":"4054_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478\u20131483","journal-title":"N Engl J Med"},{"key":"4054_CR15","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1681\/ASN.V3121938","volume":"3","author":"R Mathias","year":"1993","unstructured":"Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children\u2019s hospital. J Am Soc Nephrol 3:1938\u20131946","journal-title":"J Am Soc Nephrol"},{"key":"4054_CR16","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00467-014-2919-z","volume":"30","author":"NM Khouzam","year":"2015","unstructured":"Khouzam NM, Wesseling-Perry K, Salusky IB (2015) The role of bone in CKD-mediated mineral and vascular disease. Pediatr Nephrol 30:1379\u20131388","journal-title":"Pediatr Nephrol"},{"key":"4054_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nrneph.2011.139","volume":"7","author":"CP Schmitt","year":"2011","unstructured":"Schmitt CP, Mehls O (2011) Mineral and bone disorders in children with chronic kidney disease. Nat Rev Nephrol 7:624\u2013634","journal-title":"Nat Rev Nephrol"},{"key":"4054_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Juppner H, Salusky IB (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79:112\u2013119","journal-title":"Kidney Int"},{"key":"4054_CR19","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1210\/jc.2008-0660","volume":"93","author":"JA Sosa","year":"2008","unstructured":"Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA (2008) Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 93:3058\u20133065","journal-title":"J Clin Endocrinol Metab"},{"key":"4054_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.sempedsurg.2014.03.003","volume":"23","author":"JF Burke","year":"2014","unstructured":"Burke JF, Chen H, Gosain A (2014) Parathyroid conditions in childhood. Semin Pediatr Surg 23:66\u201370","journal-title":"Semin Pediatr Surg"},{"key":"4054_CR21","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516\u20131525","journal-title":"N Engl J Med"},{"key":"4054_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CNP69269","volume":"69","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG (2008) An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69:269\u2013278","journal-title":"Clin Nephrol"},{"key":"4054_CR23","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF (2013) Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 10:e1001436","journal-title":"PLoS Med"},{"key":"4054_CR24","doi-asserted-by":"crossref","unstructured":"Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF (2014) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev:Cd006254","DOI":"10.1002\/14651858.CD006254.pub2"},{"key":"4054_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"GJ Behets","year":"2015","unstructured":"Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, D'Haese PC (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846\u2013856","journal-title":"Kidney Int"},{"key":"4054_CR26","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1111\/ajt.12911","volume":"14","author":"P Evenepoel","year":"2014","unstructured":"Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, Rutkowski B, Schaefer H, Deng H, Torregrosa JV, Wuthrich RP, Yue S (2014) A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 14:2545\u20132555","journal-title":"Am J Transplant"},{"key":"4054_CR27","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-008-0810-5","volume":"23","author":"J Muscheites","year":"2008","unstructured":"Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D (2008) Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol 23:1823\u20131829","journal-title":"Pediatr Nephrol"},{"key":"4054_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00467-009-1294-7","volume":"25","author":"C Platt","year":"2010","unstructured":"Platt C, Inward C, McGraw M, Dudley J, Tizard J, Burren C, Saleem MA (2010) Middle-term use of cinacalcet in paediatric dialysis patients. Pediatr Nephrol 25:143\u2013148","journal-title":"Pediatr Nephrol"},{"key":"4054_CR29","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00467-012-2186-9","volume":"27","author":"D Padhi","year":"2012","unstructured":"Padhi D, Langman CB, Fathallah-Shaykh S, Warady BA, Salusky IB, Lee E, Wang C, Posvar E (2012) An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatr Nephrol 27:1953\u20131959","journal-title":"Pediatr Nephrol"},{"key":"4054_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R (2009) Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 48:303\u2013311","journal-title":"Clin Pharmacokinet"},{"key":"4054_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2012.05.079","volume":"452","author":"RN Hines","year":"2013","unstructured":"Hines RN (2013) Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm 452:3\u20137","journal-title":"Int J Pharm"},{"key":"4054_CR32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1542\/peds.7.3.321","volume":"7","author":"BJ Friis-Hansen","year":"1951","unstructured":"Friis-Hansen BJ, Holiday M, Stapleton T, Wallace WM (1951) Total body water in children. Pediatrics 7:321\u2013327","journal-title":"Pediatrics"},{"key":"4054_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1399-3046.2007.00704.x","volume":"11","author":"JM Smith","year":"2007","unstructured":"Smith JM, Stablein DM, Munoz R, Hebert D, McDonald RA (2007) Contributions of the transplant registry: the 2006 annual report of the north American pediatric renal trials and collaborative studies (NAPRTCS). Pediatr Transplant 11:366\u2013373","journal-title":"Pediatr Transplant"}],"updated-by":[{"DOI":"10.1007\/s00467-018-4154-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000}}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4054-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4054-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4054-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T03:58:24Z","timestamp":1661831904000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4054-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4054"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4054-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00467-018-4154-5","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]},"assertion":[{"value":"8 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained three mistakes. In Table 1, the last line under \u201cKey Inclusion Criteria\u201d should read \u201cNormal or clinically acceptable ECGs at screening and at day \u2212\u20091.\u201d In addition, the abbreviation \u201cIP\u201d in the legend to Table 1 stands for \u201cinvestigational product.\u201d","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained three mistakes. In Table 1, the last line under \ufffd\ufffd\ufffdKey Inclusion Criteria\ufffd\ufffd\ufffd should read \ufffd\ufffd\ufffdNormal or clinically acceptable ECGs at screening and at day \ufffd\ufffd\ufffd\ufffd\ufffd\ufffd1.\ufffd\ufffd\ufffd In addition, the abbreviation \ufffd\ufffd\ufffdIP\ufffd\ufffd\ufffd in the legend to Table 1 stands for \ufffd\ufffd\ufffdinvestigational product.\ufffd\ufffd\ufffd","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with applicable country regulations and International Conference on Harmonization (ICH) Good Clinical Practice (GCP). The study protocol (Amgen Protocol Number 20090005;Identifier NCT01290029) was approved by the institutional review board\/independent ethics committee (IRB\/IEC) at each study center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all parents or legally acceptable representatives.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BE, EL, and WS are all employees and stockholders of Amgen, Inc. HZ is a full-time employee of Amgen, Inc. LY and BD were employees of Amgen, Inc. at the time the research was conducted. SS (S. Shahinfar Consulting, Inc.) and BW are paid consultants for Amgen, Inc. IS has research grants from Amgen, Inc. and Abbvie, Inc. and received consulting fees from Keryx, Inc. AP has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"There is a plan to share data. This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data-sharing request and also related data dictionaries, study protocol, statistical analysis plan, informed consent form, and\/or clinical study report. Data-sharing requests relating to data in this manuscript will be considered after the publication date, and (1) this product and indication (or other new use) have been granted marketing authorization in both the USA and Europe, or (2) clinical development discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data-sharing request for these data. Qualified researchers may submit a request containing the research objectives, the Amgen product(s), and Amgen study\/studies in scope, endpoints\/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labeling. A committee of internal advisors reviews requests. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data-sharing agreement. This may include anonymized patient data and\/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the following:.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data-sharing agreement"}}]}}